Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H P Bryer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Bone|October 1, 1996
Combined flurbiprofen and cyclosporin-A does not attenuate bone loss and exaggerates renal impairmentD A Sass, B Rucinski, H P Bryer, et al.
Calcified Tissue International|January 1, 1995
Amylin increases bone volume but cannot ameliorate diabetic osteopeniaD F Romero, H P Bryer, B Rucinski, et al.
Endocrinology|June 1, 1996
T lymphocytes play a critical role in the development of cyclosporin A-induced osteopeniaF J Buchinsky, Y Ma, G N Mann, et al.
Bone|June 27, 2001
Transforming growth factor-beta administration modifies cyclosporine A-induced bone lossG R Goodman, I R Dissanayake, A R Bowman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 1, 1995
Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the ratH P Bryer, J A Isserow, E C Armstrong, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 1, 1995
Bone mineral metabolism in T lymphocyte-deficient and -replete strains of ratF J Buchinsky, Y Ma, G N Mann, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 1, 1995
Rapamycin: a bone sparing immunosuppressant?D F Romero, F J Buchinsky, B Rucinski, et al.
Calcified Tissue International|July 1, 1996
Short-term systemic insulin-like growth factor-1 is unable to prevent cyclosporin A-induced osteopenia in the ratG N Mann, D A Sass, H K Chen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Bone|October 1, 1996
Combined flurbiprofen and cyclosporin-A does not attenuate bone loss and exaggerates renal impairmentD A Sass, B Rucinski, H P Bryer, et al.
Calcified Tissue International|January 1, 1995
Amylin increases bone volume but cannot ameliorate diabetic osteopeniaD F Romero, H P Bryer, B Rucinski, et al.
Endocrinology|June 1, 1996
T lymphocytes play a critical role in the development of cyclosporin A-induced osteopeniaF J Buchinsky, Y Ma, G N Mann, et al.
Bone|June 27, 2001
Transforming growth factor-beta administration modifies cyclosporine A-induced bone lossG R Goodman, I R Dissanayake, A R Bowman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 1, 1995
Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the ratH P Bryer, J A Isserow, E C Armstrong, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 1, 1995
Bone mineral metabolism in T lymphocyte-deficient and -replete strains of ratF J Buchinsky, Y Ma, G N Mann, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 1, 1995
Rapamycin: a bone sparing immunosuppressant?D F Romero, F J Buchinsky, B Rucinski, et al.
Calcified Tissue International|July 1, 1996
Short-term systemic insulin-like growth factor-1 is unable to prevent cyclosporin A-induced osteopenia in the ratG N Mann, D A Sass, H K Chen, et al.
Pageof 1